David Cotter, MD, PhD

The panel introduces Case 3—a patient with established CSU, co-existing dermatographia, and incomplete prior treatment records—and discusses how to confirm the diagnosis and prepare for advanced therapy.

The panel discusses how to navigate treatment selection when patients have preferences and how to compare the available advanced therapies.

The panel provides a detailed breakdown of how a BTK inhibitor works in CSU and reviews key findings from the pivotal clinical trials

The panel explores how to assess the full impact of CSU when the skin looks normal, and how to approach the transition to advanced targeted therapy.

The panel introduces Case 2—a more severe patient with daily CSU, recurrent angioedema, throat tightness, and prior emergency department visits.

The panel addresses the role of allergy and immunology in CSU care and argues for a collaborative, access-focused approach between specialties.

The panel turns to treatment strategy—discussing appropriate antihistamine use, dose escalation, and when to move to advanced therapies.

The panel explores how to differentiate CSU from chronic inducible urticaria and acute urticaria, including the potential for overlap between subtypes.

The panel examines how to distinguish CSU from other urticaria subtypes, how to approach angioedema, and how limited—or expansive—the diagnostic workup should be.

The panel reviews the first patient case—a 38-year-old woman with recurrent hives and intermittent swelling—highlighting the key clinical criteria that clinch a CSU diagnosis.

The panel reflects on dermatology's evolving role in CSU, from limited options and reluctance to a new era of empowered, effective disease management.

Discover how JAK inhibitors reshape AD care with rapid relief, smart safety screening, and emerging personalized strategies that guide real-world treatment choices.

At AAD 2026, Christopher Bunick, MD, PhD, and David Cotter, MD, PhD, discuss data suggesting tirzepatide may augment ixekizumab responses in psoriatic arthritis—potentially independent of weight loss.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

At DERM 2025, David Cotter, MD, PhD, shared how GEP testing revolutionizes skin cancer management and enhances patient care at the forefront of dermatology innovation.

Dermatology has the opportunity of directing and leading AI use in the field, according to David Cotter, MD, PhD.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.

An expert discusses when gene expression profile (GEP) testing is recommended for melanoma and squamous cell carcinoma (SCC) patients, including cases where it may not be necessary, and provides final thoughts on the utility of GEP testing in risk stratification and making treatment decisions.

An expert discusses their impressions of the case, classifying the patient’s risk based on the clinical presentation of the lesion, and outlines treatment recommendations without knowing the 40-gene expression profile (GEP) information, including whether adjuvant therapy (ART) would be recommended. The expert also shares how to discuss 40-GEP testing with patients and reassure them that accurate risk levels are crucial for receiving optimal treatment.

An expert discusses initial thoughts on the case, including the risk category the patient would fall into based on the characteristics of their lesion, outlines the treatment guidelines for melanoma based on their risk, and suggests the frequency of surveillance visits solely based on their traditional risk classification.

An expert discusses the detection of circulating tumor DNA (ctDNA) prior to surgery, noting higher detection rates in stage III patients compared with stage IIB/C patients, and its significant association with a greater number of involved lymph nodes, extracapsular extension, and clinically evident disease, while also highlighting that all 6 patients with ctDNA detected during the surveillance period developed recurrent melanoma. The expert also provides an overview of the 40-gene expression profile (GEP) test for squamous cell carcinoma (SCC) risk stratification and discusses its utility.

An expert discusses the qualities of genetic tests that are most important to clinicians seeking precise and reliable results for melanoma diagnosis and prognosis, and reviews the 31-gene expression profile (GEP) test, highlighting its ability to classify melanoma risk into 1A, 1B, 2A, and 2B, with 1A patients showing higher melanoma-specific survival (MSS) and overall survival (OS), while 1B/2A and 2B classifications serve as independent predictors of MSS and OS, noting that patients who underwent 31-GEP testing had lower mortality compared with untested patients.

An expert discusses the patient demographics and clinical features used in traditional staging and risk classification of melanoma and squamous cell carcinoma (SCC), examining how staging systems from organizations like the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) align in risk classification, the challenges of relying solely on clinical features for prognosis, and the importance of accurate risk staging in guiding treatment decisions for these cancers.